Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD (DEFEND) Clinical Trial
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The DEFEND trial will be the world's first clinical trial to study the effectiveness of Paxlovid or Veklury in the prevention of cardiovascular post-acute sequelae of SARS-CoV-2 among hospitalized adults. Additionally, this pilot study will inform the design and conduct of a future full-scale multi-centre trial by testing the feasibility and accuracy of this study design.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• ≥18 years old
• Positive PCR test for SARS-CoV-2 within 5 days of admission to hospital
• Normoxic (not receiving supplemental oxygen)
• Able to provide informed written consent (or, if patient is unable, have substitute decision maker available)
Locations
Other Locations
Canada
Kingston Health Sciences Centre
NOT_YET_RECRUITING
Kingston
Niagara Health System
NOT_YET_RECRUITING
St. Catharines
Mount Sinai Hospital, Sinai Health System
RECRUITING
Toronto
St. Joseph's Health Centre, Unity Health Toronto
NOT_YET_RECRUITING
Toronto
Contact Information
Primary
Dr. Kieran Quinn
kieran.quinn@mail.utoronto.ca
416-843-8403
Time Frame
Start Date: 2025-01-03
Estimated Completion Date: 2027-01
Participants
Target number of participants: 118
Treatments
Experimental: Paxlovid
Paxlovid vs. placebo
Experimental: Veklury
Veklury vs. placebo
Related Therapeutic Areas
Sponsors
Collaborators: Niagara Health System, Unity Health Toronto, Kingston Health Sciences Centre
Leads: Mount Sinai Hospital, Canada